Affordable Access

deepdyve-link
Publisher Website

The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.

Authors
  • de Lissovoy, Gregory
  • Fraeman, Kathy
  • Salon, Jeff
  • Chay Woodward, Tatia
  • Sterz, Raimund
Type
Published Article
Journal
Journal of Medical Economics
Publisher
Informa UK Limited
Publication Date
Jan 01, 2008
Volume
11
Issue
3
Pages
415–429
Identifiers
DOI: 10.3111/13696990802291679
PMID: 19450096
Source
Medline
License
Unknown

Abstract

At an acquisition cost of euro600 per vial, there is at least 50% likelihood that levosimendan is cost effective relative to dobutamine if willingness to pay is equal to or greater than euro15,000 per life year gained.

Report this publication

Statistics

Seen <100 times